Navigation Links
Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric,Academic Societies' Annual Meeting

upplemental oxygen, which increases their risk of developing BPD. Discovery believes that after an initial RDS treatment, BPD may be successfully treated with repeated doses of a non-immunogenic, precision-engineered synthetic surfactant (Surfaxin) to improve the clinical outcome of these infants.

Discovery's Proprietary KL-4 Surfactant Technology: Product Candidates Surfaxin(r) and Aerosurf(tm)

Discovery's surfactant product candidates, including Surfaxin and Aerosurf, are engineered versions of natural human lung surfactant and contain the precision-engineered KL-4 peptide. KL-4 is a 21 amino acid protein-like substance that is designed to closely mimic the essential attributes of human surfactant protein B (SP-B), the surfactant protein most important for the proper functioning of the respiratory system. KL-4 surfactant has the potential to be precisely formulated, either as a liquid instillate, aerosolized liquid or dry powder, to address various respiratory diseases affecting premature infants, children and adults.

Surfaxin, a precision-engineered Surfactant Replacement Therapy (SRT) administered as a liquid-instillate, represents a potential alternative to animal-derived surfactants. Surfaxin's precision-engineered and non-immunogenic nature allows it to be further developed as a therapeutic to address other pulmonary conditions in neonatal and pediatric medicine. Data from Discovery's pivotal, multinational SELECT study demonstrate that Surfaxin is significantly more effective in the prevention of RDS and results in improved survival (continuing through at least one year of life) and other outcomes versus comparator surfactants. The SELECT and STAR (a supportive Phase 3 study) trials, as well as a pooled Phase 3 analysis, have been presented at several international medical meetings and the results from the two studies were published in Pediatrics.

Aerosurf is a precision-engineered, aerosolized SRT administered via nasal continuou
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
2. Discoverys KL-4 Surfactant Technology Demonstrates Novel Anti-Inflammatory Properties
3. Major Discovery Raises Prospect of Better Patient Care By Improving Platelet Life Span
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
6. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
7. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
8. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
9. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
10. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
11. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
Post Your Comments:
(Date:8/28/2015)... 2015  Delays in the launch and execution ... the decision-making process, resulting in missed opportunities and ... biopharmaceutical companies to develop a tactical approach to ... and more meaningful insights. According ... three-quarters of benchmarked study participants use review cycle ...
(Date:8/28/2015)... , Aug. 28, 2015 ... has announced the addition of the "Investigation ... to their offering. Originally discovered by ... Yoshitomi Pharmaceutical Industries, Ltd) as an inflammatory drug, ... Senju Pharmaceutical Co., Ltd under the trade name ...
(Date:8/28/2015)... , Aug. 28, 2015 ... addition of the "Investigation Report on China,s Tobramycin ... Tobramycin is a traditional antibiotic whose eye drop and ... treatment of potential infection or inflammation caused by eye ... are able to produce tobramycin, among which ...
Breaking Medicine Technology:Expediting the Pharmaceutical Market Research Process for Faster Insights 2Investigation Report on China's Pranoprofen Market, 2010-2019 2Investigation Report on China's Tobramycin Market, 2015-2019 2
... N.Y., Oct. 25, 2011 Misonix, Inc. (NASDAQ: ... that designs, manufactures and markets innovative therapeutic ultrasonic ... surgery, neurosurgery, laparoscopic surgery, and other surgical and ... the BoneScalpel™ Ultrasonic Bone Cutting System at the ...
... HIGHLIGHTS:2011 Results (all percentages are to comparable periods in 2010) ... to $626 million. Q3 sales grew organically by 4% with ... 4% and 2%, respectively.  Recently completed acquisitions contributed an additional ... additional 5% to reported sales growth in Q3. ...
Cached Medicine Technology:Misonix Exhibits BoneScalpel™ at the International Meeting on Advanced Spine Techniques 2Misonix Exhibits BoneScalpel™ at the International Meeting on Advanced Spine Techniques 3Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 2Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 3Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 4Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 5Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 6Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 7Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 8Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 9Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 10Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 11Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 12Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 13
(Date:8/28/2015)... , ... August 28, 2015 , ... ... or those who might personally be struggling with chemical dependency, may be able ... Best Drug Rehabilitation, a results-driven holistic treatment center for addiction located in Western ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... Library for documenting and diagramming network and data center assets and audio-video devices, ... Device Model, Cisco Nexus 5000 Series, HP ProLiant Gen9, EMC VNX Series , ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Nashville ... military veterans leading in business. Mr. Troy Mizell, Chairman of the Board ... Nashville Business Journal's 2015 Veterans Awards will recognize Nashville military veterans who, through ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... loyalty at a low cost. Personalized with practice contact information and logos, Calendars ... Dental offices can also incorporate Calendars into seasonal mailings, thank you and welcome ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... Mendon, IL, ... of good music and good people, all for a good cause. In its second ... 2015, sponsored once more by Best Drug Rehabilitation. The “Mission” of “Music With A ...
Breaking Medicine News(10 mins):Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 2Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 3Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 2Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 3Health News:MyGenetx Board Member Receives Veterans Award 2Health News:SmartPractice® Introduces 2016 Calendars for Dental Practice Giveaways 2Health News:Best Drug Rehabilitation Sponsors "Music With A Mission" Concert Featuring Avenue Beat 2
... ... One online magazine and website, www.usariseup.com , provides a forum to have an ... ... the heated debates raging over immigration, America,s multi-racial, multi-ethinic society is still the foundation ...
... for suspected pulmonary embolism test negative, researchers find , TUESDAY, ... necessary in many patients suspected of having a blood clot ... identify those most likely to require the procedure, a new ... clot, usually from the leg, moves through the bloodstream and ...
... ... Medical Genetics to meet virtual repository technology needs of the network, , ... Reston, VA (PRWEB) June 15, ... American College of Medical Genetics (ACMG) has selected the company to contribute web-based applications ...
... ... “Learn More” series , ... NY (PRWEB) June 15, 2010 -- VoIP Supply, North America’s leading supplier of Voice over ... Buyers Guide . The VoIP Phone Buyers Guide is the second guide to be released ...
... ... York-based tutoring , testing and coaching center Brain Academy has once again helped a ... learning. Brain Academy,s unique focus on cognitive improvement is not only academically effective, but ... subjects. , ...
... ... Enthusiastically Embrace Any Innovation That Enables Them To Fit The Care Of Their Parents Into ... ... person over the age of 65 will need some form of long term care during ...
Cached Medicine News:Health News:Why A Multi-Racial, Multi-Ethnic Society Needs Open and Sustained Dialogue 2Health News:Why A Multi-Racial, Multi-Ethnic Society Needs Open and Sustained Dialogue 3Health News:Docs Should Assess Lung Clot Risk Before Ordering Scan 2Health News:Technology Innovation Advances Newborn Screen Translational Research Network 2Health News:Technology Innovation Advances Newborn Screen Translational Research Network 3Health News:VoIP Supply Releases VoIP Phone Buyers Guide 2Health News:Brain Academy's Revolutionary New Approach to Tutoring and Test Prep Helps Students Find Academic Success 2Health News:Brain Academy's Revolutionary New Approach to Tutoring and Test Prep Helps Students Find Academic Success 3Health News:Brain Academy's Revolutionary New Approach to Tutoring and Test Prep Helps Students Find Academic Success 4Health News:Brain Academy's Revolutionary New Approach to Tutoring and Test Prep Helps Students Find Academic Success 5Health News:Online Services Will Energise The Country's Invisible Healthcare Service 2Health News:Online Services Will Energise The Country's Invisible Healthcare Service 3
... RNA Mini Kit allows purification ... cell-free fluid samples. Examples of ... be isolated with this kit ... to, RNA from hepatitis A, ...
The Mago® Plus Automated EIA Analyzer is a fully automated, integrated ELISA system. Together, with immunosimplicity® reagents, the Mago® Plus provides a flexible, integrated solution ...
... computer-enhanced microplate reader with a ... flexible and rapid photometric analysis. ... and reliable photometric measurement of ... shaking before reading) and can ...
The Rapidpoint 400/405 instrument is a point-of-care blood gas analyzer that's fast, easy to operate and reliable....
Medicine Products: